Penicillin G (Parenteral/Aqueous)

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Penicillin G; Belgium: Penicilline; Bulgaria: Penicillin G; Estonia: Pencillin; Finland: Benzylpenicillin, Geepenil; France: Penicilline G; Germany: Clemizol Penicillin, Penicillin G; Greece: Penicilline; Hungary: Penicillin G; Ireland: Crystapen; Italy: Penicillina G; Luxembourg: Penicilline; Netherlands: Bicilline, Penicilline G; Poland: Penicillin G; Spain: Neopenyl, Penibiot, Penicilina G, Penilevel, Sodiopen, Unicilina; Sweden: Bensylpenicillin, Benzylpenicillin; UK: Crystapen.

North America

Canada: Pfizerpen; USA: Pfizerpen.

Latin America

Mexico: Declín, Kavipén, Pecivax, Pendibén, Penicil, Penisodina, Prosodina, Sodilín, Suipén.

Drug combinations

Chemistry

Penicillin G Sodium: C~16~H~17~N~2~NaO~4~S. Mw: 356.37. (1) 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, [2S-(2α,5α,6β)]-, monosodium salt; (2) Monosodium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. CAS-69-57-8; CAS-61-33-6 (penicillin G).

Penicillin G Potassium: C~16~H~17~KN~2~O~4~S. Mw: 372.48. (1) 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, monopotassium salt, [2S-(2α,5α,6β)]-; (2) Monopotassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. CAS-113-98-4.

Pharmacologic Category

Natural Penicillins. (ATC-Code: J01CE).

Mechanism of action

Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria.

Therapeutic use

Treatment of infections (including sepsis, pneumonia, pericarditis, endocarditis, meningitis, anthrax) caused by susceptible organisms. Active against some Gram-positive organisms, generally not Staphylococcus aureus. Some Gram-negative organisms such as Neisseria gonorrhoeae, and some anaerobes and spirochetes.

Pregnancy and lactiation implications

Adverse events not observed in animal studies. Penicillin crosses placenta and distributes into amniotic fluid. No evidence of adverse fetal effects after penicillin use during pregnancy in humans. Penicillin G is drug of choice for treatment of syphilis during pregnancy, and penicillin G (parenteral/aqueous) is drug of choice for prevention of early-onset Group B streptococcal disease in newborns. Caution when administering penicillin to nursing women.

Unlabeled use

Contraindications

Hypersensitivity to penicillin or any component of the formulation.

Warnings and precautions

Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions reported, especially with history of β-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (use with caution in asthmatic patients). Avoid intra-arterial administration or injection into or near major peripheral nerves or blood vessels since such injections may cause severe and/or permanent neurovascular damage. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment, and in history of seizure disorder (high levels, particularly in the presence of renal impairment, may increase risk of seizures). Neonates may have decreased renal clearance of penicillin (dosage adjustments). Product contains sodium and potassium (high doses of I.V. therapy may alter serum levels). Prolonged use or use associated with high serum concentrations (e.g. in renal insufficiency) may be associated with increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart